Concord Biotech Ltd Technical Momentum Shifts Signal Bullish Outlook

Technical Momentum and Indicator Analysis

Concord Biotech’s current market price stands at ₹1,469.70, up 1.89% from the previous close of ₹1,442.50, with intraday highs reaching ₹1,489.80 and lows at ₹1,439.00. The stock remains comfortably above its 52-week low of ₹987.05, though still shy of its 52-week high of ₹1,702.10. This price action reflects a recovery phase with positive momentum building.

Examining the Moving Average Convergence Divergence (MACD) indicator, the weekly chart signals a bullish crossover, indicating increasing upward momentum in the near term. However, the monthly MACD remains mildly bearish, suggesting that while short-term momentum is strengthening, longer-term trends require further confirmation before a sustained uptrend can be declared.

The Relative Strength Index (RSI) on both weekly and monthly timeframes currently shows no definitive signal, hovering in neutral territory. This implies that the stock is neither overbought nor oversold, providing room for further price appreciation without immediate risk of a technical reversal due to exhaustion.

Bollinger Bands reinforce the bullish sentiment, with both weekly and monthly charts indicating upward price pressure. The stock price is trending near the upper band on the weekly scale, signalling strong buying interest and potential continuation of the rally.

Daily moving averages have turned bullish, with the stock price trading above key averages such as the 50-day and 200-day moving averages. This alignment is a classic technical confirmation of an upward trend, often attracting momentum traders and institutional interest.

Conversely, the Know Sure Thing (KST) indicator on the weekly chart remains bearish, which introduces a note of caution. The absence of a clear monthly KST reading leaves some ambiguity regarding the strength of the trend over longer periods. Additionally, Dow Theory analysis shows no definitive trend on weekly or monthly charts, and On-Balance Volume (OBV) also remains neutral, indicating volume has not decisively confirmed price moves.

Price Performance Relative to Sensex

Concord Biotech’s price returns over various periods reveal a mixed but generally positive trend relative to the broader market benchmark, the Sensex. Over the past week, the stock declined by 0.92%, outperforming the Sensex’s sharper fall of 1.78%. This relative resilience is noteworthy in a volatile market environment.

Over the last month, Concord Biotech surged 7.47%, significantly outpacing the Sensex’s decline of 3.72%. Year-to-date (YTD) returns further highlight the stock’s strength, with a 9.23% gain compared to the Sensex’s 11.32% loss. These figures underscore the company’s ability to buck broader market trends, likely driven by sector-specific catalysts and improving technicals.

However, the one-year return shows a negative 8.73%, slightly underperforming the Sensex’s 6.45% loss, indicating some recent challenges or profit-taking phases. Longer-term performance over three years is robust, with a 44.96% gain versus the Sensex’s 13.48%, reflecting strong fundamental growth and investor confidence in the company’s prospects.

Data for five and ten-year returns are not available for Concord Biotech, but the Sensex’s 29.75% and 160.21% gains respectively provide a benchmark for comparison.

Mojo Score and Rating Upgrade

MarketsMOJO has upgraded Concord Biotech’s Mojo Grade from Sell to Hold as of 31 July 2026, reflecting improved technical and fundamental outlooks. The current Mojo Score stands at 57.0, placing the stock in the Hold category within the Pharmaceuticals & Biotechnology sector. This upgrade signals a shift in analyst sentiment, recognising the stock’s emerging bullish momentum and relative strength.

As a small-cap stock, Concord Biotech’s market capitalisation remains modest, which can contribute to higher volatility but also offers potential for outsized gains if positive trends continue. Investors should weigh the technical signals alongside fundamental factors and sector dynamics before making allocation decisions.

Investor Considerations and Outlook

From a technical perspective, Concord Biotech’s transition to a bullish trend on weekly charts, supported by MACD and Bollinger Bands, alongside daily moving averages, suggests that momentum is building in favour of higher prices. The neutral RSI readings imply that the stock is not yet overextended, allowing room for further gains.

However, the bearish weekly KST and lack of confirmation from Dow Theory and OBV indicators counsel caution. These mixed signals highlight the importance of monitoring volume trends and broader market conditions to confirm the sustainability of the current rally.

Fundamentally, the company’s outperformance relative to the Sensex over the medium term and the recent upgrade in Mojo Grade to Hold indicate improving investor sentiment. Yet, the one-year negative return and small-cap status suggest that volatility remains a factor, and investors should consider risk management strategies accordingly.

In summary, Concord Biotech Ltd presents a technically improving profile with emerging bullish momentum, supported by key indicators and relative strength versus the benchmark. While some caution is warranted due to mixed signals and market uncertainties, the stock’s recent upgrade and price action make it a noteworthy candidate for investors seeking exposure to the Pharmaceuticals & Biotechnology sector’s growth potential.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →